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Abstract 
Background: Systemic sclerosis (SSc) is a complex autoimmune disease characterized by vascular alterations and 
autoimmune activation leading to widespread organ fibrosis. At the early stage of disease when organ involvement 
and extent of disease are emerging, mast cells may have some role, as implied by both symptoms and histologic 
evidence.
Case presentation: A female patient diagnosed with cutaneous mastocytosis experienced the onset of systemic 
sclerosis after 15 years followed by the switch of mastocytosis to the systemic phenotype. A literature review on the 
evidences related to mast-cells activation in systemic sclerosis is presented below.
Conclusions: For clinicians, more attention must be paid to the potential association between systemic sclerosis 
and cancer. This case suggests that a proliferative disease in the mast cell compartment—though representing a rare 
association—may not be completely unexpected in SSc and perhaps excess mast cell activity can serve a pathogenic 
role in promoting fibrotic disease.
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Background
Systemic sclerosis (SSc) is a connective tissue disorder 
characterized by autoimmune activation and endothe-
lial dysfunction leading to fibrotic changes of the skin 
and internal organs [1]. The clinical presentation of this 
disease is highly heterogeneous. In addition, predic-
tion of the ultimate pattern of specific internal organ 
involvement, as well as the development of overlap fea-
tures, is difficult at the time of the diagnosis [2]. Early in 
the course, patients with SSc skin disease report pruri-
tus, being described frequently as the most bothersome 
symptom [3–5]. Among 400 patients, 45 % reported pru-
ritus with a disease duration of at least 1 year, increasing 
to 69 % when considering only patients with 1–2 years of 
disease duration [6]. Lip biopsy in very early stages of SSc 
reveals that mast cell infiltration starts before the disease 
acquires definite features [7]. Biopsy of involved skin 
of SSc patients confirms that mast cells (MC) reside in 
proximity of fibroblasts, produce TGF-β and the number 
of degranulated cells is particularly increased [8]. More 
specifically, the MCT (tryptase-positive, chymase-nega-
tive) are more prominent in SSc lesional skin compared 
to MCTC (tryptase-positive, chymase-positive) type of 
mast cell that represents the normal population of mast 
cell in healthy subjects [9].
Nevertheless, it remains unclear whether the switch 
toward a specific population of MC favours fibroblast 
proliferation through the release of tryptase, but it might. 
The early phase of SSC includes interstitial oedema and 
pruritus, the corticosteroid responsive so-called “puffy 
hands” phase of SSc clinically. Mast cell mediator release 
may promote the early phase of interstitial oedema and 
pruritus through histamine and the processing of big-
endothelin in endothelium through chymase, as evi-
denced in rat lungs. On the other hand, mast cells can 
also counteract collagen deposition through matrix met-
alloproteinase activation [10].
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Although mastocytosis is rare in any setting, the inci-
dence of malignancy in general in SSc is increased com-
pared to the general population (pooled standardized 
incidence ration 1.41 for all cancers). The incidence of 
cancer is higher within the first 12 months after the ini-
tial SSc diagnosis [11]. In population-based studies of 
SSc patients, it has been reported that the hematologic 
malignancies are primarily non-Hodgkin lymphomas 
and leukemias [12], and in female subjects hematologic 
cancer is more frequent [13]. Consequently, a prolif-
erative disease in the mast cell compartment—though 
representing a rare association—may not be completely 
unexpected in SSc. In this report, we call attention to 
a case of patient who developed SSc after, rather than 
before, a diagnosis of cutaneous mastocytosis, and in 
whom the mastocytosis became more extensive after the 
SSc became manifest.
Case presentation
A 36 year-old woman presented with complaints of dys-
phagia, fatigue, widespread pain and muscle weakness 
localized mainly at the inferior limbs. Fifteen years prior, 
she was diagnosed with cutaneous mastocytosis, con-
firmed by skin biopsy. Over the 6  months, she noticed 
worsening of Raynaud’s phenomenon and thickening of 
the skin over the hands and feet. She underwent vide-
ocapillaroscopy revealing an active scleroderma pattern 
and was diagnosed with systemic sclerosis. Laboratory 
test showed ANA positivity with high titers (1:2560, 
granular pattern) and anti-SSa. Four months later, she 
was admitted to the hospital due to worsening dysphagia, 
fatigue and muscle weakness.
Clinical examination revealed body temperature 
36.5  °C, blood pressure 127/80  mmHg and a regular 
pulse of 76 beats/min. No superficial lymph adenopathy 
was evident. Skin thickening (Rodnan skin score 28/51) 
and spleen enlargement were noted, however. Laboratory 
tests revealed that rheumatoid factor, as well as anti-SS-
B, anti-Sm, anti-Scl-70, anti-centromere, anti-Jo1 and 
anti-DNA antibodies were all negative. Serum levels of 
CK 350 U/L (n.v.197 U/L), LDH 652 U/L (n.v. 200 U/L), 
myoglobin (421 ng/mL n.v. 0–70 ng/mL), SGOT 47 U/L 
(n.v. 29 U/L), SGPT 71 U/L (n.v. 51 U/L) were elevated. 
The serologic HLA typing was A1, B51 and CW7 for class 
I and DQ7, DR11 and DR52 for class II.
Ultrasound examination of the spleen confirmed the 
physical examination finding. Echocardiographic exami-
nation was relevant for an increase in pulmonary arterial 
pressure (40 mmHg). Due to the suspicion of the onset of 
a systemic mastocytosis, based on the involvement of the 
spleen and vertebral pain, the patient underwent bone 
marrow biopsy, PET and total body CT. Bone marrow 
biopsy result confirmed an intense infiltration of mast 
cells triptase+ , CD25+ , CD117+ , CD123+ , CD45RB/
LCA+  , CD68+  , CD14±  ,CD20−, CD30−. PET scan 
showed thoracic and abdominal lymph nodes, spleen and 
sacrum uptake. CT scan detected widespread lytic lesion 
of the chest and vertebral bones, basilar reticulonodular 
infiltrates, and spleen enlargement. Electromyography 
was compatible with an inflammatory myopathy.
The patient started therapy with prednisone at the dose 
of 50 mg day, nifedipine 10 mg day, mycophenale mofetil 
at the dose of 2  g  day and iloprost infusions 0.05  mg 
every day per 3  days every month. She underwent full 
evaluation in a heamotologic center located in a differ-
ent hospital, and received zoledronic acid for osteolytic 
lesions. After 2 months, the patient’s myalgias and fatigue 
improved, as confirmed by serology, as well as her verte-
bral pain. The addition of a chemotherapeutic agent for 
systemic mastocytosis is now under consideration.
Conclusions
A previous case series study described this rare asso-
ciation in which systemic sclerosis precedes the onset of 
cutaneous mastocytosis [14], perhaps suggesting some 
underlying stimulation of the mast cell compartment as a 
feature of the SSc. The investigators reported two cases of 
skin lesions associated with mast-cell infiltrates compat-
ible with the diagnosis of cutaneous mastocytosis at 30 
and 6 years after the onset of SSc. In contrast, in our case, 
the initial cutaneous mastocytosis has an interplay with 
SSc in which cutaneous mastocytosis precedes the onset 
of systemic sclerosis, perhaps suggesting  that excess 
mast cell activity can serve a pathogenic role in promot-
ing fibrotic disease. The onset of SSc in this case in turn 
was subsequently accompanied by the progression of the 
cutaneous form of mastocytosis into the widespread sys-
temic phenotype. This case therefore raises the possibility 
that, the link between mast cell activity and fibrotic dis-
ease may ultimately be understood as a bidirectional one, 
or a feedback loop.
Several lines of evidence support the involvement of 
mast-cells in the pathogenesis of SSc [15, 16]: in the tight 
skin mouse model of SSc the proliferation and activa-
tion of mast-cells leads to augmentation of fibrosis; an 
increase of dermal mast cell density is typical of the early 
phase of the disease [17]; mast cells are involved in the 
development of interstitial oedema [18]; the degranula-
tion of mast-cells is considered one of the mechanisms 
leading to TGF-β secretion in SSc [19]. Indeed, mast cells 
granules contain several profibrotic moelcules, such as 
TGF-β itself and also PDGF and VEGF, plus other mole-
cules that favour myofibroblast transdiferrentiation, such 
as IL-4 and GM-CSF [20].
Of note, among the chemotherapeutic agents availa-
ble for the treatment of mastocytosis, a small tyrosine 
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kinase inhibitor, imatinib mesylate, has indications 
for specific forms of this malignancy (without the 
D816 V c-Kit mutation or with c-Kit mutational status 
unknown) [21] though it failed in SSC [22]. Similarly, 
in SSc another related tyrosine kinase inhibitor, nint-
edanib, has gained increasing attention as a potential 
therapeutic agent in interstitial pulmonary fibrosis. 
Promising results have been reported in animal mod-
els [23] and in clinical trials related to skin fibrosis 
and lung function [24]. Nintedanib is now in clini-
cal trial for ILD due to SSc. If tyrosine kinase inhibi-
tors are found to play a role in therapeutic regimens 
aimed at fibrotic diseases such as idiopathic pulmo-
nary fibrosis (IPF) and systemic sclerosis associated 
interstitial lung disease (SSc–ILD), it may be that they 
work in part by inhibition of slower, chronic, non-ana-
phylactic transdegraulation of mast cells, among other 
mechanisms.
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